Eli Lilly Trial Finds Alzheimer’s Drug Can Slow Progress of Disease

Eli Lilly Trial Finds Alzheimer’s Drug Can Slow Progress of Disease

The New York Times - Business:

Donanemab is not a cure and comes with significant side effects, but patients had longer periods of independent living while on the drug.

This post first appeared in The New York Times - Business. Read the original article.